Print
Email
Print Edition StoriesFriday, August 7, 2009
Molecular Insight anti-cancer drug speeds into Phase 2 trials
By Mass High Tech staff
MHT's Galen Moore: Hiring trends and opportunities
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Researchers focus on macular degeneration
Cambridge-based Molecular Insight Pharmaceuticals Inc. has entered Phase 2 clinical trials with its neuroendocrine cancer treatment, Azedra, the company announced today. The treatment has been given Orphan Drug with Fast Track status by the U.S. Food and Drug Administration.
Azedra is designed to treat adult patients suffering from malignant relapsed/refractory pheochromocytoma, a tumor often found in the adrenal glands. The company said it expects the trial to test the effectiveness of Azedra in 58 adults in order for the company to file a New Drug Application. If it’s approved, Molecular Insight (Nasdaq: MIPI) officials said it would be the first anti-cancer treatment in the U.S. for pheochromocytoma. The company is also planning to apply Azedra as a treatment for children’s neuroendocrine cancer, neuroblastoma.
Azedra, if effective, would treat the sometimes-severely elevated blood pressure and heart rate symptoms associated with the tumors.
Founded in 1997 (as Imaging Biopharmaceuticals Inc.), Cambridge-based Molecular Insight specializes in the development of radiotherapeutics and molecular-imaging agents in the fields of oncology and cardiology.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
